S&P 500   3,970.99
DOW   32,237.53
QQQ   310.89
MarketBeat Week in Review – 3/20 - 3/24
Fed's Shocking New Plan to Control Your Money (Ad)
Germany, EU reach agreement in combustion engine row
Intel co-founder, philanthropist Gordon Moore dies at 94
Fed's Shocking New Plan to Control Your Money (Ad)
Judge rules online archive's book service violated copyright
Biden's moves on Alaska drilling, TikTok test young voters
Fed's Shocking New Plan to Control Your Money (Ad)
Ruling halts oil exports from Iraq's Kurdish area via Turkey
Finnish leadership condemns attack on veteran lawmaker
S&P 500   3,970.99
DOW   32,237.53
QQQ   310.89
MarketBeat Week in Review – 3/20 - 3/24
Fed's Shocking New Plan to Control Your Money (Ad)
Germany, EU reach agreement in combustion engine row
Intel co-founder, philanthropist Gordon Moore dies at 94
Fed's Shocking New Plan to Control Your Money (Ad)
Judge rules online archive's book service violated copyright
Biden's moves on Alaska drilling, TikTok test young voters
Fed's Shocking New Plan to Control Your Money (Ad)
Ruling halts oil exports from Iraq's Kurdish area via Turkey
Finnish leadership condemns attack on veteran lawmaker
S&P 500   3,970.99
DOW   32,237.53
QQQ   310.89
MarketBeat Week in Review – 3/20 - 3/24
Fed's Shocking New Plan to Control Your Money (Ad)
Germany, EU reach agreement in combustion engine row
Intel co-founder, philanthropist Gordon Moore dies at 94
Fed's Shocking New Plan to Control Your Money (Ad)
Judge rules online archive's book service violated copyright
Biden's moves on Alaska drilling, TikTok test young voters
Fed's Shocking New Plan to Control Your Money (Ad)
Ruling halts oil exports from Iraq's Kurdish area via Turkey
Finnish leadership condemns attack on veteran lawmaker
S&P 500   3,970.99
DOW   32,237.53
QQQ   310.89
MarketBeat Week in Review – 3/20 - 3/24
Fed's Shocking New Plan to Control Your Money (Ad)
Germany, EU reach agreement in combustion engine row
Intel co-founder, philanthropist Gordon Moore dies at 94
Fed's Shocking New Plan to Control Your Money (Ad)
Judge rules online archive's book service violated copyright
Biden's moves on Alaska drilling, TikTok test young voters
Fed's Shocking New Plan to Control Your Money (Ad)
Ruling halts oil exports from Iraq's Kurdish area via Turkey
Finnish leadership condemns attack on veteran lawmaker
NASDAQ:HLVX

HilleVax - HLVX Stock Forecast, Price & News

$15.29
-0.07 (-0.46%)
(As of 03/24/2023 12:00 AM ET)
Add
Compare
Today's Range
$15.00
▼
$15.44
50-Day Range
$15.00
▼
$18.18
52-Week Range
$7.90
▼
$24.42
Volume
29,649 shs
Average Volume
44,979 shs
Market Capitalization
$600.13 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$32.00

HilleVax MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
109.3% Upside
$32.00 Price Target
Short Interest
N/A
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
1.13mentions of HilleVax in the last 14 days
Based on 12 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($3.96) to ($3.64) Per Share

Overall MarketRank™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.24 out of 5 stars

Medical Sector

339th out of 1,005 stocks

Biological Products, Except Diagnostic Industry

58th out of 168 stocks

See Top Rated MarketRank™ Stocks Here

HLVX stock logo

About HilleVax (NASDAQ:HLVX) Stock

HilleVax, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel vaccines. It is developing HIL-214, a virus-like particle-based vaccine candidate for the prevention of moderate-to-severe acute gastroenteritis caused by norovirus and related illness. The company was formerly known as MokshaCo, Inc. and changed its name to HilleVax, Inc. in February 2021. HilleVax, Inc. was founded in 2019 and is headquartered in Boston, Massachusetts.

Receive HLVX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for HilleVax and its competitors with MarketBeat's FREE daily newsletter.

HLVX Stock News Headlines

March 25, 2023 | americanbankingnews.com
Q1 2023 Earnings Estimate for HilleVax, Inc. (NASDAQ:HLVX) Issued By SVB Leerink
March 22, 2023 | americanbankingnews.com
HilleVax, Inc. (NASDAQ:HLVX) to Post Q1 2024 Earnings of ($0.91) Per Share, SVB Leerink Forecasts
March 26, 2023 | Weiss Ratings (Ad)
Fed's Shocking New Plan to Control Your Money
The Federal Reserve has a disturbing plan that is getting ready to roll out as soon as May. This is a lot more than printing trillions of dollars or manipulating interest rates. It's about every checking account, every purchase and every money transfer in America — including yours and mine. 
March 20, 2023 | finanznachrichten.de
HilleVax, Inc.: HilleVax Reports Full Year 2022 Financial Results and Highlights Recent Company Progress
March 17, 2023 | finance.yahoo.com
HilleVax Reports Full Year 2022 Financial Results and Highlights Recent Company Progress
March 17, 2023 | americanbankingnews.com
HilleVax (NASDAQ:HLVX) Shares Down 10.3%
March 16, 2023 | americanbankingnews.com
HilleVax (NASDAQ:HLVX) vs. Elevation Oncology (NASDAQ:ELEV) Critical Contrast
January 9, 2023 | finance.yahoo.com
HilleVax Announces Executive Management Appointments and Promotions
March 26, 2023 | Weiss Ratings (Ad)
Fed's Shocking New Plan to Control Your Money
The Federal Reserve has a disturbing plan that is getting ready to roll out as soon as May. This is a lot more than printing trillions of dollars or manipulating interest rates. It's about every checking account, every purchase and every money transfer in America — including yours and mine. 
January 4, 2023 | finance.yahoo.com
HilleVax to Present at the 41st Annual J.P. Morgan Healthcare Conference
December 30, 2022 | bizjournals.com
HilleVax, Boston’s biggest IPO of 2022, wants to end common norovirus effect
December 14, 2022 | finance.yahoo.com
After Plunging 32.4% in 4 Weeks, Here's Why the Trend Might Reverse for HilleVax, Inc. (HLVX)
December 13, 2022 | finance.yahoo.com
Down 25.2% in 4 Weeks, Here's Why You Should You Buy the Dip in HilleVax, Inc. (HLVX)
December 7, 2022 | markets.businessinsider.com
SVB Securities Keeps Their Buy Rating on HilleVax, Inc (HLVX)
December 5, 2022 | markets.businessinsider.com
HilleVax Reports Positive Immunogenicity Results For Phase 2b Trial For HIL-214
December 5, 2022 | finance.yahoo.com
HilleVax Announces Positive Immunogenicity Results for Run-In Cohort of NEST-IN1 Phase 2b Clinical Trial of HIL-214 Norovirus Vaccine Candidate
November 18, 2022 | finance.yahoo.com
Here's Why "Trend" Investors Would Love Betting on HilleVax, Inc. (HLVX)
November 15, 2022 | finance.yahoo.com
Wall Street Analysts Predict a 67% Upside in HilleVax, Inc. (HLVX): Here's What You Should Know
November 14, 2022 | markets.businessinsider.com
SVB Securities Reaffirms Their Buy Rating on HilleVax, Inc (HLVX)
November 11, 2022 | finanznachrichten.de
HilleVax, Inc.: HilleVax Reports Third Quarter 2022 Financial Results and Highlights Recent Company Progress
November 10, 2022 | finance.yahoo.com
HilleVax Reports Third Quarter 2022 Financial Results and Highlights Recent Company Progress
November 10, 2022 | finance.yahoo.com
HilleVax to Participate in November Investor Conferences
September 2, 2022 | barrons.com
HilleVax Inc.
September 1, 2022 | tmcnet.com
HilleVax to Participate in J.P. Morgan Biotech - 2022 Conference Call Series
September 1, 2022 | finance.yahoo.com
HilleVax to Participate in J.P. Morgan Biotech – 2022 Conference Call Series
August 31, 2022 | finance.yahoo.com
HilleVax Announces Positive Recommendation from Safety Data Monitoring Committee for NEST-IN1 Phase 2b Clinical Trial of HIL-214 Norovirus Vaccine Candidate
August 15, 2022 | finance.yahoo.com
HilleVax to Participate in Fireside Chat at the SVB Securities Virtual Vaccine Forum
See More Headlines
Receive HLVX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for HilleVax and its competitors with MarketBeat's FREE daily newsletter.

HLVX Company Calendar

Today
3/25/2023
Next Earnings (Estimated)
6/14/2023
Fiscal Year End
12/31/2023
Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Industry
Biological products, except diagnostic
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:HLVX
CUSIP
N/A
CIK
1888012
Web
www.hillevax.com
Phone
617-213-5054
Fax
N/A
Employees
15
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$32.00
High Stock Price Forecast
$40.00
Low Stock Price Forecast
$24.00
Forecasted Upside/Downside
+109.3%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
4 Analysts

Profitability

EPS (Most Recent Fiscal Year)
($13.10)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-159,810,000.00
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
-92.75%
Return on Assets
-58.37%

Debt

Debt-to-Equity Ratio
0.06
Current Ratio
22.28
Quick Ratio
34.77

Sales & Book Value

Annual Sales
N/A
Price / Sales
N/A
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
N/A
Price / Book
N/A

Miscellaneous

Outstanding Shares
39,250,000
Free Float
27,594,000
Market Cap
$600.13 million
Optionable
Not Optionable
Beta
N/A

Key Executives

  • Dr. Robert M. Hershberg M.D.Dr. Robert M. Hershberg M.D. (Age 61)
    Ph.D., Pres, CEO & Chairman
    Comp: $611.2k
  • Mr. David A. SocksMr. David A. Socks (Age 48)
    CFO & Chief Bus. Officer
    Comp: $561.72k
  • Mr. Aditya Kohli Ph.D. (Age 35)
    COO & Director
    Comp: $576.55k
  • Dr. Anju Chatterji Ph.D.
    Sr. VP of Technical Operations
  • Mr. Paul S. Bavier J.D. (Age 51)
    Gen. Counsel, Sec. & Chief Admin. Officer
  • Ms. Astrid Borkowski M.D. (Age 53)
    Ph.D., Chief Medical Officer
  • Ms. Kaia Agarwal
    Sr. VP of Regulatory Affairs

Key Competitors

View All Competitors

Institutional Ownership

View All Institutional Transactions













HLVX Stock - Frequently Asked Questions

Should I buy or sell HilleVax stock right now?

4 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for HilleVax in the last year. There are currently 4 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" HLVX shares.
View HLVX analyst ratings or view top-rated stocks.

What is HilleVax's stock price forecast for 2023?

4 Wall Street research analysts have issued 1 year price targets for HilleVax's shares. Their HLVX share price forecasts range from $24.00 to $40.00. On average, they predict the company's share price to reach $32.00 in the next twelve months. This suggests a possible upside of 109.3% from the stock's current price.
View analysts price targets for HLVX or view top-rated stocks among Wall Street analysts.

How have HLVX shares performed in 2023?

HilleVax's stock was trading at $16.73 at the beginning of 2023. Since then, HLVX stock has decreased by 8.6% and is now trading at $15.29.
View the best growth stocks for 2023 here.

When is HilleVax's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, June 14th 2023.
View our HLVX earnings forecast.

What ETFs hold HilleVax's stock?

ETFs with the largest weight of HilleVax (NASDAQ:HLVX) stock in their portfolio include Direxion mRNA ETF (MSGR), ETFMG Treatments Testing and Advancements ETF (GERM), ALPS Medical Breakthroughs ETF (SBIO), Invesco Nasdaq Biotechnology ETF (IBBQ) and ProShares Ultra Nasdaq Biotechnology (BIB).

When did HilleVax IPO?

(HLVX) raised $200 million in an initial public offering (IPO) on Friday, April 29th 2022. The company issued 11,765,000 shares at $16.00-$18.00 per share.

What is HilleVax's stock symbol?

HilleVax trades on the NASDAQ under the ticker symbol "HLVX."

Who are HilleVax's major shareholders?

HilleVax's stock is owned by a number of retail and institutional investors. Top institutional investors include Braidwell LP (4.86%), Franklin Resources Inc. (3.74%), T. Rowe Price Investment Management Inc. (3.63%), Morgan Stanley (1.82%), Geode Capital Management LLC (0.83%) and Charles Schwab Investment Management Inc. (0.31%).

How do I buy shares of HilleVax?

Shares of HLVX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is HilleVax's stock price today?

One share of HLVX stock can currently be purchased for approximately $15.29.

How much money does HilleVax make?

HilleVax (NASDAQ:HLVX) has a market capitalization of $600.13 million. The company earns $-159,810,000.00 in net income (profit) each year or ($13.10) on an earnings per share basis.

How can I contact HilleVax?

The official website for the company is www.hillevax.com. The company can be reached via phone at 617-213-5054 or via email at ir@hillevax.com.

This page (NASDAQ:HLVX) was last updated on 3/26/2023 by MarketBeat.com Staff